Food noise is a popular term for persistent, unwanted, intrusive thoughts about food. Some people taking GLP-1 medications such as semaglutide report that those thoughts get quieter. Researchers have now proposed formal definitions of the term. The food noise GLP-1 evidence is early. It rests on anecdotal reports, patient interviews and reviews, and none of the studies reviewed here is a randomized trial. Food noise is not a medical diagnosis.

Key takeaways

What is food noise? The definitions researchers use

Food noise is persistent, unwanted thinking about food that feels intrusive or distressing. There are two published research definitions, but food noise is not a formal medical diagnosis.

The term started as everyday language. A 2023 narrative review in Nutrients noted anecdotal reports from patients and clinicians of less rumination and obsessive preoccupation with food on GLP-1 receptor agonists like semaglutide (Nutrients, 2023). GLP-1 receptor agonists are medications that mimic a gut hormone involved in appetite and blood sugar.

Hayashi and colleagues, the review's authors, argued that scientists have long studied a close relative of food noise called food cue reactivity. Food cue reactivity is how your body and mind respond to food signals such as the sight, smell or thought of food. The authors proposed the Cue–Influencer–Reactivity–Outcome (CIRO) model as a framework for future research. Their definition describes food noise as "heightened and/or persistent manifestations of food cue reactivity, often leading to food-related intrusive thoughts and maladaptive eating behaviors" (Nutrition & Diabetes, 2026).

In 2025, an expert panel agreed on a second definition. Food noise is persistent thoughts about food that a person perceives as unwanted or dysphoric (unpleasant or distressing) and that may cause social, mental or physical harm (Nutrition & Diabetes, 2025).

Food noise differs from ordinary food cue reactivity in quality: the Hayashi definition marks it out by its heightened, persistent and disruptive character. A 2026 analysis of TikTok videos found that over three-quarters of coded videos described food noise in line with that definition, though some used the term for ordinary hunger, appetite and craving (Nutrition & Diabetes, 2026).

How is food noise measured?

The food noise evidence reviewed here relies on self-report and patient description, not objective measures.

That includes anecdotal reports, interviews and social media posts. Brain-imaging studies come closer to an objective measure, but they measure something adjacent. Functional MRI (fMRI) is a scan that tracks brain activity while, for example, a person views pictures of food. A 2026 review acknowledges that neither of the neuroimaging studies it discusses directly measured food noise (Cureus, 2026).

Self-reports capture how people perceive their own thoughts, not brain activity, eating or weight change.

Food noise and GLP-1 medications: the evidence, ranked

Patients, clinicians and interview participants report that GLP-1 medications quiet food noise. That evidence sits on the lower rungs of the evidence ladder, and none of the sources reviewed here is a randomized trial measuring food noise.

Randomized trials rank highest because chance decides who gets the drug. That separates the drug's effect from the traits of people who choose to take it.

RungExampleWhat it can showMain limits
Randomized trialNone among the sources reviewed hereWhether the drug itself changes food noiseNot available in this evidence set
Qualitative interviewsJAMA Network Open, 2026What people describe, in their own wordsCan't show how common an experience is
Reviews and modelsNutrients 2023, Cureus 2026, bioRxiv 2026Frameworks and possible mechanismsDon't measure food noise in patients directly
Anecdotal reportsNoted in Nutrients 2023 and bioRxiv 2026That an experience is worth studyingNo systematic data collection or comparison group

The qualitative study is the most direct peer-reviewed evidence in this set. Researchers ran semistructured video interviews with 30 adults living in the United States between July and September 2025. Participants had taken a GLP-1 for any reason; 23 were current users and 7 had stopped, with a mean age of 54. The first of eight themes the researchers identified was a reduction in food noise, psychological hunger or appetite. Participants described the drugs as a facilitator rather than a replacement for lifestyle change. Other themes included a wide spectrum of adverse effects, willingness to tolerate them, stigma, highly variable clinical support, and cost and access barriers. The authors called for standardized patient education and clinical support alongside behavioral interventions (JAMA Network Open, 2026).

Participants were recruited through ResearchMatch, a volunteer research registry, and snowball sampling, where participants refer others. The study was funded by the Stanford Center for Digital Health. A self-selected group like this suits exploring experiences, but it can't show how common an experience is, compare users with a control group or measure change.

A 2026 systematic review, posted as a preprint, states plainly that reports of GLP-1s reducing food noise are anecdotal (bioRxiv preprint, 2026).

Put together, the evidence shows that people report quieter food noise on GLP-1s and that researchers have plausible frameworks for why. It does not show whether the drug causes the change, how common it is, how fast it happens or whether it lasts after stopping.

Why might GLP-1s quiet intrusive thoughts about food?

No one knows for certain. Researchers have proposed three overlapping hypotheses, drawn from reviews and brain-imaging research.

  1. Blunted food cue reactivity. If food noise is heightened reactivity to food cues, as the CIRO model proposes, a drug that dampens that reactivity could make food thoughts fade. CIRO is a research framework, not a proven pathway (Nutrients, 2023).
  2. Reward circuitry. The 2026 systematic review describes food noise as related to craving. It reviewed fMRI studies of how GLP-1s affect responses to food cues in obesity and to drug cues in substance use disorders (bioRxiv preprint, 2026).
  3. The default mode network. The default mode network is a set of brain regions active during mind-wandering and thinking about the future. A 2026 narrative review proposes that food noise is a loop of intrusive, future-oriented thoughts about eating driven by this network. It cites evidence that the insula's response to tempting food cues drops with GLP-1 use. The insula is a brain region that helps process internal body signals (Cureus, 2026).

These mechanisms are plausible, but none is settled. Simple single-chemical explanations go beyond what the evidence shows. Food noise is also only one part of how these drugs act on the body. For trial data on body composition, see our guide to GLP-1 muscle loss and lean mass.

When quieter food noise could be a concern

For most people in these reports, less food noise reads as relief. For someone with a history of restrictive eating, less interest in food can reinforce harmful patterns.

Intrusive food thoughts occur in people with and without eating disorders (Nutrients, 2023). The same quiet that feels freeing to one person can make restriction easier for another. Research on GLP-1 use in people with a history of restrictive eating is limited.

Two practical points help:

Is food noise a reason a clinician would prescribe a GLP-1?

No FDA label lists food noise as an indication. The Wegovy label covers uses including weight reduction and cardiovascular risk reduction in adults (FDA Wegovy label, 2026).

Whether a GLP-1 is appropriate depends on your intake and clinical review, including your medical history and contraindications. Not everyone qualifies, and that's how it should work. It is reasonable to mention food noise at intake as context about how you experience eating. Mentioning it doesn't make a prescription more likely. Our GLP-1 eligibility checklist explains what clinicians typically screen for.

Questions worth raising with a clinician:

  1. Given my full medical history, is a GLP-1 appropriate for me at all?
  2. Does my eating history change how you'd approach this?
  3. What should I do if my appetite drops so low that I skip meals?
  4. Which side effects should I report, and how quickly?
  5. How does medication fit alongside nutrition, activity and other support?

Who should not use GLP-1 medications?

People with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2), or a history of pancreatitis, should not use these medications. A licensed clinician screens for these conditions during intake review.

MTC is a rare thyroid cancer. MEN 2 is an inherited syndrome that raises the risk of it. The Wegovy label contraindicates semaglutide in people with either history. It carries a boxed warning because semaglutide caused thyroid C-cell tumors in rodents, and whether it causes them in humans is unknown. The label also contraindicates use in people with known hypersensitivity to semaglutide or its ingredients (FDA Wegovy label, 2026).

On pancreatitis, the label reports acute pancreatitis with GLP-1 receptor agonists, including Wegovy, and this includes fatal and non-fatal hemorrhagic or necrotizing cases. The 2021 Wegovy label stated the drug had not been studied in people with a history of pancreatitis (FDA Wegovy label, 2026). This label information describes the FDA-approved brand product, not compounded versions. For more detail, read semaglutide pancreatitis risk in trials and labels.

How access works through New Blue

New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.

  1. You complete an asynchronous intake, a structured health questionnaire about your medical history.
  2. A licensed clinician reviews it and decides whether treatment is appropriate. Some treatments or states may require a live visit. Consultation timing varies by clinician availability.
  3. If prescribed, a licensed partner pharmacy ships the medication directly to you.

Compounded semaglutide is not FDA-approved. It has the same active ingredient as Ozempic and Wegovy, which are FDA-approved brand products, but it is not equivalent to them or a generic of them. Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities. Our guide to branded vs compounded GLP-1s explains the difference.

Availability varies by state. The Semaglutide GLP-1 pathway has delivery limits in some states. Check state availability before you start. Current pricing is on the Semaglutide GLP-1 pathway page. If treatment isn't appropriate, refunds follow our refund policy. Care is for adults 21 and older and is not for emergencies. New Blue is LegitScript certified.

Frequently Asked Questions

Is food noise a real medical condition?

Food noise is not a medical diagnosis. It has two published research definitions, one from a 2023 conceptual model and one from a 2025 expert panel. It describes a real experience, but it isn't a condition a clinician diagnoses.

Does semaglutide get rid of food noise?

No study can promise that for any individual. A 2026 systematic review describes reports of GLP-1s reducing food noise as anecdotal (bioRxiv preprint, 2026). A qualitative interview study also reported reduced food noise as a theme among users. Neither is a randomized trial, and individual experiences vary.

How soon do people notice a change in food noise?

The evidence can't answer this for any individual. None of the studies reviewed here measured how quickly food noise changes after starting a GLP-1, and personal timing depends on factors they didn't examine.

Does food noise come back if you stop a GLP-1?

The sources reviewed here don't answer this. None of them tracked food noise after people stopped a GLP-1. Any confident claim either way goes beyond the current evidence.

Can behavior change reduce food noise without medication?

It may, but the evidence here doesn't settle it. The sources reviewed here did not directly test behavioral approaches on food noise. The authors of one interview study called for clinical support alongside behavioral interventions.

Should I tell my clinician about past disordered eating?

Yes. Quieter food thoughts can reinforce restrictive patterns, and your history helps a clinician decide whether a GLP-1 is appropriate. Disclosing it is part of safe care, not a barrier to it.

Sources

  1. What Is Food Noise? A Conceptual Model of Food Cue Reactivity. Nutrients, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10674813/
  2. Food noise: definition, measurement, and future research directions. Nutrition & Diabetes, 2025. https://doi.org/10.1038/s41387-025-00382-x
  3. Patient Experiences With GLP-1 Receptor Agonists. JAMA Network Open, 2026. https://pubmed.ncbi.nlm.nih.gov/42247231/
  4. WEGOVY (semaglutide) injection and tablets: Highlights of Prescribing Information. U.S. Food and Drug Administration, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
  5. Quieting "Food Noise": How GLP-1s and Mindfulness Rewire the Default Mode Network (DMN) and Reward Circuits. Cureus, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12770913/
  6. Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-Related Cues? A Systematic Review. bioRxiv (preprint), 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12889473/
  7. 'And just like that, quiet': a content analysis of TikTok videos on food noise. Nutrition & Diabetes, 2026. https://www.nature.com/articles/s41387-026-00423-z

Medical disclaimer: This article is for educational purposes only and is not medical advice. Decisions about whether any treatment is appropriate are made by a licensed clinician based on your intake and clinical review. New Blue Health is a technology and administrative services platform, not a medical provider.

Related treatment guide

Related reading

Content review & editorial standards

This page is educational content from the New Blue Health Editorial Team. It is checked under the New Blue Health Content Review Policy and Editorial Policy and should not replace individualized medical advice from a licensed clinician. For how we evaluate evidence, see Evidence Methodology and Clinical Sources & References.

Start Your Visit